NEW YORK – Immunotherapy developer Advaxis and sequencing firm Personalis said today that they have entered an extended collaboration agreement, under which they are using Personalis' ImmunoID NeXT Platform for biomarker discovery in Advaxis' ongoing Phase I/II program advancing the investigational ADXS-503 alone and in combination with pembrolizumab for patients with non-small cell lung cancer.
Menu
To read the full story....
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
By Hera Biolabs
By Asuragen
Mar
31
Sponsored by
Isoplexis
Sponsorships
Privacy Policy. Terms & Conditions. . Copyright © 2020 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.